IRIS
ZANGHI', AURORA
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 1.883
EU - Europa 1.294
AS - Asia 1.130
Continente sconosciuto - Info sul continente non disponibili 475
SA - Sud America 286
AF - Africa 26
OC - Oceania 8
Totale 5.102
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 1.820
SG - Singapore 521
IE - Irlanda 386
RU - Federazione Russa 280
BR - Brasile 241
IT - Italia 217
CN - Cina 205
HK - Hong Kong 145
VN - Vietnam 106
FR - Francia 88
DE - Germania 78
SE - Svezia 71
BD - Bangladesh 50
FI - Finlandia 48
GB - Regno Unito 43
CA - Canada 31
AR - Argentina 17
IN - India 17
TR - Turchia 17
NL - Olanda 16
MX - Messico 13
PL - Polonia 13
IQ - Iraq 11
ID - Indonesia 10
EC - Ecuador 9
ES - Italia 8
AT - Austria 7
IR - Iran 7
ZA - Sudafrica 7
AU - Australia 6
JP - Giappone 6
PK - Pakistan 6
BE - Belgio 5
CH - Svizzera 5
CL - Cile 5
EG - Egitto 5
AE - Emirati Arabi Uniti 4
CR - Costa Rica 4
HN - Honduras 4
HU - Ungheria 4
MA - Marocco 4
SA - Arabia Saudita 4
VE - Venezuela 4
AL - Albania 3
CO - Colombia 3
DZ - Algeria 3
PH - Filippine 3
PT - Portogallo 3
PY - Paraguay 3
RO - Romania 3
UZ - Uzbekistan 3
CI - Costa d'Avorio 2
DO - Repubblica Dominicana 2
HR - Croazia 2
JO - Giordania 2
LT - Lituania 2
MD - Moldavia 2
OM - Oman 2
PS - Palestinian Territory 2
QA - Qatar 2
TT - Trinidad e Tobago 2
UA - Ucraina 2
UY - Uruguay 2
VC - Saint Vincent e Grenadine 2
XK - ???statistics.table.value.countryCode.XK??? 2
AM - Armenia 1
AZ - Azerbaigian 1
BB - Barbados 1
BO - Bolivia 1
BS - Bahamas 1
CZ - Repubblica Ceca 1
DK - Danimarca 1
ET - Etiopia 1
GA - Gabon 1
GR - Grecia 1
IS - Islanda 1
JM - Giamaica 1
KE - Kenya 1
KN - Saint Kitts e Nevis 1
KR - Corea 1
KZ - Kazakistan 1
LB - Libano 1
LV - Lettonia 1
MK - Macedonia 1
NO - Norvegia 1
NP - Nepal 1
NZ - Nuova Zelanda 1
PE - Perù 1
SC - Seychelles 1
SK - Slovacchia (Repubblica Slovacca) 1
SV - El Salvador 1
TG - Togo 1
TH - Thailandia 1
TO - Tonga 1
Totale 4.629
Salva come PNG Salva come JPEG
Città #
San Jose 495
Dublin 385
Singapore 198
Ashburn 190
Hong Kong 140
Beijing 110
Chandler 87
Santa Clara 81
Council Bluffs 75
Nyköping 70
Columbus 67
Lauterbourg 59
Princeton 41
Ho Chi Minh City 39
Helsinki 34
Los Angeles 33
Dallas 29
Munich 27
Wilmington 27
São Paulo 25
New York 24
Frankfurt am Main 21
Naples 21
Hanoi 19
Moscow 17
London 15
Milan 15
Turku 14
Phoenix 13
Assago 12
Rome 12
Bari 11
Des Moines 11
Seattle 11
Warsaw 11
Hillsboro 10
Rio de Janeiro 10
Chicago 9
Nuremberg 9
Atlanta 8
Falkenstein 8
Kocaeli 8
San Francisco 8
Düsseldorf 7
Guangzhou 7
Hudson 7
Belo Horizonte 6
Brooklyn 6
Buffalo 6
Curitiba 6
Montreal 6
Toronto 6
Ankara 5
Biên Hòa 5
Frattamaggiore 5
Mexico City 5
Murrysville 5
North Bergen 5
Ottawa 5
Paris 5
Tehran 5
The Dalles 5
Thái Bình 5
Tokyo 5
Washington 5
Alessandria 4
Cairo 4
Campinas 4
Cedar Knolls 4
Denver 4
Francavilla Fontana 4
Johannesburg 4
Long Beach 4
Miami 4
Newark 4
Ninh Bình 4
Orem 4
Quito 4
Reston 4
Ribeirão Preto 4
San José 4
San Severo 4
Sorocaba 4
Tsuen Wan 4
Ufa 4
Vienna 4
Anápolis 3
Boston 3
Brasília 3
Brussels 3
Buenos Aires 3
Bắc Ninh 3
Can Tho 3
Caxias do Sul 3
Chennai 3
Contagem 3
Da Nang 3
Guarulhos 3
Haiphong 3
Jiaxing 3
Totale 2.757
Salva come PNG Salva come JPEG
Nome #
Exit Strategies in Natalizumab-Treated RRMS at High Risk of Progressive Multifocal Leukoencephalopathy: a Multicentre Comparison Study 123
MicroRNAs 181a and 125a are highly expressed in naïve RRMS: a pilot case-control study 120
Is It Time for Ocrelizumab Extended Interval Dosing in Relapsing Remitting MS? Evidence from An Italian Multicenter Experience During the COVID-19 Pandemic 105
IMMUNOSENESCENCE AND MULTIPLE SCLEROSIS: PROGNOSTIC AND THERAPEUTIC IMPLICATIONS 105
Are oligoclonal bands associated to lower retinal layer thickness at the time of relapsing remitting multiple sclerosis diagnosis? Evidence from an exploratory study 105
Real world comparison of teriflunomide and dimethyl fumarate in naïve relapsing multiple sclerosis patients: Evidence from the Italian MS register 103
Editorial: Immunosenescence and multiple sclerosis: Prognostic and therapeutic implications 101
Comparing STRATIFY JCV™ DxSelect™ and IMMUNOWELL™ JCV IgG Tests in RRMS to Assess PML Risk 101
A Personalized Approach in Progressive Multiple Sclerosis: The Current Status of Disease Modifying Therapies (DMTs) and Future Perspectives 101
Effectiveness and safety of Rituximab in demyelinating diseases spectrum: An Italian experience 99
Cancer Risk and Multiple Sclerosis: Evidence From a Large Italian Cohort 97
Can new chemical therapies improve the management of multiple sclerosis in children? 96
An update on the safety of treating relapsing-remitting multiple sclerosis 96
Dimethyl fumarate vs Teriflunomide: an Italian time-to-event data analysis 94
Discontinuation of teriflunomide and dimethyl fumarate in a large Italian multicentre population: a 24-month real-world experience 92
Comparable efficacy and safety of dimethyl fumarate and teriflunomide treatment in Relapsing-Remitting Multiple Sclerosis: an Italian real-word multicenter experience 92
Disease trajectory in secondary progressive multiple sclerosis: a ten years follow-up study 91
Late-onset and young-onset relapsing-remitting multiple sclerosis: evidence from a retrospective long-term follow-up study 90
Stopping Interferon Beta 1b Does Not Influence the Risk of Disability Accrual in Non-Active SPMS: Results from an Italian Real-World Study 89
An Association of Framingham Risk Score with Patient Determined Disease Steps in a Cohort of Relapsing-Remitting Multiple Sclerosis Patients: An Italian Real-World Monocentric Experience 86
Evaluating Cognitive Outcomes in Multiple Sclerosis: Real-World Impact of Ozanimod on Processing Speed Using BICAMS 84
Unraveling the inflammation-degeneration tangle in early MS: preliminary insights from ferritin, neurogranin, TREM2, and retinal ganglion cell layer 82
First-line therapies in Late Onset Multiple Sclerosis: an Italian registry study 82
Management of dysphagia in multiple sclerosis: current best practice 81
Switching disease-modifying therapy in multiple sclerosis: escalation therapy has not an advantage on switching among same line drugs 79
Metabolic Abnormalities, Dietary Risk Factors and Nutritional Management in Amyotrophic Lateral Sclerosis 77
Exploring polypharmacy phenomenon in newly diagnosed relapsing–remitting multiple sclerosis: a cohort ambispective single-centre study 76
Personality Traits and Fatigue in Multiple Sclerosis: A Narrative Review 75
Pregnancy and the Postpartum Period in Women With Relapsing-Remitting Multiple Sclerosis Treated With Old and New Disease-Modifying Treatments: A Real-World Multicenter Experience 75
Myeloid-derived Suppressor Cells and Multiple Sclerosis 73
Identifying Cladribine prescription pattern in MS: an Italian multicentre study 73
Ocrelizumab Extended Interval Dosing in Primary Progressive Multiple Sclerosis: An Italian Experience 73
The Neutrophil-to-Lymphocyte Ratio is Related to Disease Activity in Relapsing Remitting Multiple Sclerosis 72
Gonadal Steroids and Sperm Quality in a Cohort of Relapsing Remitting Multiple Sclerosis: A Case-Control Study 72
Palliative care in progressive multiple sclerosis 71
A multimodal approach to distinguish multiple sclerosis phenotypes at diagnosis using biomarker profiles 70
Injectable Versus Oral First-Line Disease-Modifying Therapies: Results from the Italian MS Register 69
Male fertility in relapsing-remitting multiple sclerosis patients treated with natalizumab and ocrelizumab: A prospective case-control study 69
MiRNA 106a-5p in cerebrospinal fluid as signature of early relapsing remitting multiple sclerosis: a cross sectional study 67
Injectable versus oral first-line multiple sclerosis therapies: knows and unknowns from observational studies 67
Multiple sclerosis from onset to secondary progression: a 30-year Italian register study 64
Neural precursor cells tune striatal connectivity through the release of IGFBPL1 64
Immunosuppression in relapsing remitting multiple sclerosis: moving towards personalized treatment 64
Monocytic myeloid derived suppressor cells in hematological malignancies 64
Ocrelizumab and ofatumumab comparison: an Italian real-world propensity score matched study 62
Lateral and escalation therapy in relapsing-remitting multiple sclerosis: a comparative study 61
Pharmacotherapeutic management of lower urinary tract symptoms in Multiple Sclerosis Patients 61
Ofatumumab and Early Immunological Cells Subset Characterization in Naïve Relapsing Multiple Sclerosis Patients: A Real-World Study 60
Relapse-associated worsening in a real-life multiple sclerosis cohort: The role of age and pyramidal phenotype 60
Lateral switch to IFN beta-1a 44 mcg may be effective as escalation switch to fingolimod in selected persons with relapsing remitting multiple sclerosis: a real-world setting experience 60
Personalized Therapy in Multiple Sclerosis: state of art and future perspectives 60
Real-world comparison of Dimethyl-fumarate and teriflunomide in treatment-naive and non responders patients with relapsing remitting multiple sclerosis: preliminary data of a multicenter, prospectie study 60
Immunological Subsets Characterization in Newly Diagnosed Relapsing–Remitting Multiple Sclerosis 58
Mental health status of relapsing-remitting multiple sclerosis Italian patients returning to work soon after the easing of lockdown during COVID-19 pandemic: A monocentric experience 58
Switching therapy: how and why in a real word setting cohort of persons with multiple sclerosis in Catania 58
Real-World comparison of reasons for changing treatment to dimethyl-fymarate or teriflunomide in non responders patients with relapsing remitting multiple sclerosis: preliminary results of a multicenter prospective study 57
Treatment-Related Progressive Multifocal Leukoencephalopathy in Multiple Sclerosis: A Comprehensive Review of Current Evidence and Future Needs 57
Real-world comparison of safety profile in two groups of relapsing remitting multiple sclerosis on dimethyl-fumarate and teriflunomide therapy: preliminary results of a multicenter, prospective study 56
Placing CD20-targeted B cell depletion in multiple sclerosis therapeutic scenario: Present and future perspectives 55
Quality of care provided by Multiple Sclerosis Centers during Covid-19 pandemic: Results of an Italian multicenter patient-centered survey 52
Positioning siponimod and the post-treatment gap: the unmet needs of SPMS patients in Italian real-world practice 52
Prevalence and predictors of bowel dysfunction in a large multiple sclerosis outpatient population: an Italian multicenter study 49
Siponimod following Alemtuzumab in secondary progressive MS: investigating sequential therapy-A case series 49
Pharmacoeconomics of synthetic therapies for multiple sclerosis 48
Modeling lymphocyte subset dynamics after ublituximab therapy in patients with multiple sclerosis: an Italian prospective study 47
New treatment targets in multiple sclerosis therapy 47
Combined biologic therapy targeting B cells and eosinophils in relapsing multiple sclerosis and severe asthma: a case report of ofatumumab and mepolizumab 34
Cognitive and structural brain changes in ofatumumab-treated multiple sclerosis: A longitudinal study 32
Cortical Atrophy and Cognitive Outcomes in Relapsing MS Patients Treated With Ofatumumab: a Real-World Longitudinal Study 29
Transitioning from intravenous to subcutaneous ocrelizumab in a high-volume infusion center: A time-and-motion-informed capacity and service-flow analysis 20
Making the invisible audible: a real-world connected speech study in myasthenia gravis 17
Multidomain Fatigue, Cognitive, and Quality of Life Observations in Generalized Myasthenia Gravis Under Ravulizumab: A Case Series 14
Totale 5.102
Salva come PNG Salva come JPEG
Categoria #
all - tutte 31.798
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 31.798
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2021/2022225 0 0 0 0 95 5 7 14 26 16 4 58
2022/2023722 60 18 39 47 14 44 2 37 413 19 17 12
2023/2024219 15 29 13 17 36 11 18 35 21 9 9 6
2024/20251.061 42 35 38 12 19 117 144 55 250 69 108 172
2025/20262.189 96 247 240 322 117 86 303 217 200 121 79 161
2026/2027655 65 166 172 252 0 0 0 0 0 0 0 0
Totale 5.102